About our research:
Oslo Myeloma Center is the largest center for clinical myeloma research in the Nordics.
Since 2015, 790 patients have been enrolled in 53 clinical studies in patients with smoldering multiple myeloma and multiple myeloma including newly diagnosed and relapsed/refractory patients in phase 1, 2, 3 and 4 studies.
| Year | Patient Number |
| 2015 | 83 |
| 2016 | 67 |
| 2017 | 84 |
| 2018 | 98 |
| 2019 | 120 |
| 2020 | 83 |
| 2021 | 82 |
| 2022 | 105 |
| 2023 (Until September 2023) | 114 |
Number of patients included in the different phases so far (by Sep 2023):
Phase 1 - 85 patients
Phase 2 - 290 patients
Phase 3 - 341 patients
Phase 4 - 72 patients
We collaborate with basal and translational research groups, especially with the KG Jebsen center for B cell malignancies at our hospital. In addition, we have a myeloma registry with both prospective and retrospective data.